Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

10 Clinical Trials To Watch Out For In 2023

Line Extensions To The Fore In 2023

Clinical Trial — • Source: Shutterstock

Related Content

Bullish Bayer Highlights Four Future Blockbusters

Jan 11 2023

A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA

Dec 06 2022

Lilly Does Not Expect A Quick Medicare Coverage Decision For Donanemab

Dec 15 2022

Early Adjuvant Results A Major Boost For Verzenio

Jun 17 2020

Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Jun 01 2020

ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS

Sep 21 2020

Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

Nov 22 2022

Novo Nordisk Committed To Advancing In Cardiovascular

Sep 20 2022

BTK Inhibitors Are The Next Big Race In MS

Jun 09 2022

US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s

Jan 20 2023

Related Companies

AstraZeneca PLC

Novo Nordisk A/S

Novartis AG

Roche Holding AG

Pfizer Inc.

Eli Lilly and Company

GSK plc

Sanofi

Merck KGaA

Bayer AG

Daiichi Sankyo Co., Ltd.

Gilead Sciences, Inc.

Johnson & Johnson

Eisai Co., Ltd.

Biogen, Inc.

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

KaNDy Therapeutics Ltd.

Astellas Pharma, Inc.

ImmunoGen, Inc.

BioNTech SE

Additional Topics

Clinical Trials Companies Research & Development Scrip Perspectives Cancer Metabolic Disorders Infectious Diseases Neurology BioPharmaceutical

More from Scrip Perspectives

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window